Probuphine(R) Receives FDA Priority Review Designation for Adult Patients with Opioid Dependence

Titan Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for Probuphine® has been accepted for review and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). Probuphine is a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine hydrochloride following a single treatment. Titan submitted the NDA for the maintenance treatment of opioid dependence in adult patients in October 2012 under Section 505(b)(2) of the Food, Drug and Cosmetic Act and referenced the approved sublingual tablet formulations of buprenorphine.

Priority designation is given to therapies that offer potential major advances in treatment, including improved safety, or provide a treatment where no adequate therapy exists. Based upon the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of April 30, 2013 for FDA action on the NDA.

Source: Titan Pharmaceuticals, Inc. – January 2, 2013


  1. Chris Kelly says

    Hmm, great to have another tool in the toolbox BUT what if one of these patients gets in a severe car accident? housefire? shot? The vast majority of MDs have no clue how to treat pain in bup patients. As long as doctors can be quickly schooled on pain treatment in an emergency, that would help.

    The blockade can be overcome but most doctors dont know how.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>